Gestational diabetes screening
Pro Research Analysisby 
Searched over 200M research papers
Universal Screening for Gestational Diabetes: Effectiveness and Recommendations
Universal screening for gestational diabetes is widely recommended due to the association between gestational diabetes and increased risks of adverse maternal and perinatal outcomes, such as preeclampsia, large-for-gestational-age infants, and neonatal hypoglycemia 1510. The U.S. Preventive Services Task Force (USPSTF) recommends screening all asymptomatic pregnant persons at 24 weeks of gestation or later, citing moderate certainty of a moderate net benefit in improving maternal and fetal outcomes . Community-based screening programs, such as those implemented in India, have demonstrated operational feasibility and identified a high prevalence of gestational diabetes, supporting the need for widespread screening .
Screening Methods: One-Step vs. Two-Step Approaches
There are two main approaches to gestational diabetes screening: the one-step and two-step methods. The one-step approach uses a 75-g oral glucose tolerance test (OGTT) in the fasting state, while the two-step approach starts with a 50-g glucose challenge test in the nonfasting state, followed by a 100-g OGTT if the initial test is positive 13. Research shows that the one-step approach results in nearly double the diagnosis rate of gestational diabetes compared to the two-step approach (16.5% vs. 8.5%), but there are no significant differences in key outcomes such as large-for-gestational-age infants, perinatal complications, gestational hypertension, or cesarean section rates between the two methods . The oral glucose tolerance test remains the most accepted diagnostic tool, despite practical limitations such as time, cost, and patient discomfort .
Timing and Thresholds for Screening
Most guidelines recommend screening between 24 and 28 weeks of gestation 56. The 50-g, 1-hour glucose challenge test is commonly used, with a plasma glucose threshold of 130–135 mg/dL prompting further diagnostic testing with a 3-hour OGTT 46. Lowering the threshold for further testing from 143 to 135 mg/dL increases sensitivity and helps identify more cases of gestational diabetes . Fasting glucose and random glucose tests are less commonly used due to lower sensitivity and specificity, but fasting glucose shows promise and may be validated in future studies .
Universal vs. Risk-Based Screening
Universal screening identifies more cases of gestational diabetes than risk factor-based screening, but evidence is limited regarding whether this leads to improved maternal or infant outcomes 29. Studies show that universal screening increases diagnosis rates, especially among women with lower educational levels, potentially reducing health disparities if treatment is provided . However, large effects on adverse birth outcomes such as low birth weight, macrosomia, or cesarean section can be ruled out, and more high-quality randomized controlled trials are needed to determine the true impact of universal screening on health outcomes 29.
Cost-Effectiveness and Feasibility
Screening for gestational diabetes, even among low-risk women, is considered cost-effective according to existing literature . Community-level screening using existing healthcare infrastructure is feasible and can be scaled up to reach more pregnant women, as demonstrated in large-scale projects .
Conclusion
Screening for gestational diabetes at 24 weeks of gestation or later is widely recommended and operationally feasible, with universal screening identifying more cases than risk-based approaches. The choice between one-step and two-step screening methods does not significantly affect maternal or perinatal outcomes, and the oral glucose tolerance test remains the standard diagnostic tool. While universal screening may help reduce health disparities, further research is needed to clarify its impact on long-term maternal and infant health outcomes.
Sources and full results
Most relevant research papers on this topic